XTalks

JUNE 17, 2024

Hugel, a Korean medical aesthetics company, recently announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its botulinum toxin, Letybo (letibotulinumtoxinA-wlbg), for the treatment of glabellar lines. We are thrilled with the FDA’s approval of Letybo.

FDA Approval 52

FDA Approval Marketing Botox Clinical Trials 52

The Pharma Data

JUNE 18, 2021

June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. “BOTOX ® Cosmetic is honoring and celebrating the dynamic people who use our products. IRVINE, Calif.

Botox 52

Botox Cosmetics Doctors Doctor 52

pharmaphorum

SEPTEMBER 29, 2021

AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy for episodic migraines. AbbVie acquired Qulipta in 2020 as part of its $63 billion takeover of Allergan, which also brought in Botox and Ubrelvy.

Botox 52

Botox Sales Marketing FDA Approval 52

The Pharma Data

MARCH 30, 2021

2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. IMPORTANT SAFETY INFORMATION.

Botox 52

Botox Drugs Doctors Doctor 52

The Pharma Data

NOVEMBER 2, 2020

There are a few medications approved to treat spasticity, including the generic baclofen and Botox. The FDA is expected to make a decision on Osmotica Pharmaceuticals’ arbaclofen extended release tablets for MS-associated spasticity in December. It also forced the U.S.

FDA Approval 52

FDA Approval Drugs Marketing Botox 52

XTalks

JULY 4, 2024

This journey through the pharmaceutical market will provide valuable insights into the trends shaping the healthcare industry and the innovations that continue to push the boundaries of medical science. Keytruda also won just under half a dozen FDA approvals in new oncology indications.

Sales 52

Sales Drugs FDA Approval Marketing 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. The FDA approved the drug over a decade ago in September 2009.

Sales 98

Sales Manufacturing FDA Approval Life Science 98